Karyopharm Therapeutics Inc [KPTI] stock prices are up 1.67% to $0.61 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The KPTI shares have gain 4.13% over the last week, with a monthly amount drifted -11.20%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Karyopharm Therapeutics Inc [NASDAQ: KPTI] stock has seen the most recent analyst activity on January 19, 2023, when Piper Sandler initiated its Overweight rating and assigned the stock a price target of $8. Previously, RBC Capital Mkts upgraded its rating to Outperform on November 04, 2022, and elevated its price target to $10. On February 09, 2022, upgrade upgraded it’s rating to Neutral but maintained its price target of $8 on the stock. SVB Leerink downgraded its rating to a Mkt Perform but $6 remained the price target by the analyst firm on August 06, 2021. RBC Capital Mkts downgraded its rating to Sector Perform for this stock on August 06, 2021, and downed its price target to $8. In a note dated August 06, 2021, JP Morgan downgraded an Neutral rating on this stock.
The stock price of Karyopharm Therapeutics Inc [KPTI] has been fluctuating between $0.53 and $1.70 over the past year. Currently, Wall Street analysts expect the stock to reach $7.33 within the next 12 months. Karyopharm Therapeutics Inc [NASDAQ: KPTI] shares were valued at $0.61 at the most recent close of the market. An investor can expect a potential return of 1101.64% based on the average KPTI price forecast.
Analyzing the KPTI fundamentals
The Karyopharm Therapeutics Inc [NASDAQ:KPTI] reported sales of 148.44M for trailing twelve months, representing a surge of 7.70%. Gross Profit Margin for this corporation currently stands at 0.96% with Operating Profit Margin at -0.85%, Pretax Profit Margin comes in at -0.59%, and Net Profit Margin reading is -0.59%. To continue investigating profitability, this company’s Return on Assets is posted at -0.46, Equity is 0.59 and Total Capital is -0.98. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -1.22.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.5942 points at the first support level, and at 0.5784 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.6316, and for the 2nd resistance point, it is at 0.6532.
Ratios To Look Out For
It’s worth pointing out that Karyopharm Therapeutics Inc [NASDAQ:KPTI]’s Current Ratio is 3.00. On the other hand, the Quick Ratio is 2.93, and the Cash Ratio is 1.18. Considering the valuation of this stock, the price to sales ratio is 0.52.
Transactions by insiders
Recent insider trading involved Poulton Stuart, EVP, Chief Development Officer, that happened on Feb 18 ’25 when 5914.0 shares were sold. President and CEO, Paulson Richard A. completed a deal on Feb 04 ’25 to sell 4099.0 shares. Meanwhile, President and CEO Paulson Richard A. sold 4055.0 shares on Jan 06 ’25.
